Aurobindo Pharma Limited has registered a total income of Rs.5129.1 Millions (4201.7), EBITDA of Rs.868.7 Millions (719.1) and PAT of Rs.585.4 Millions (362.1) for the quarter ended 30^th June 2007.

During the quarter the total Income, EBITDA and PAT have shown a growth of 22.1%, 20.8% and 61.7% respectively as compared to the corresponding quarter of the previous year.

Aurobindo Pharma Limited, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients.

The company has received approvals for most of the targeted API and formulation facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa.

The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. 

The formulation portfolio is built on six technology platforms such as immediate release generics, SR/CR generics, and Orally disintegrating/Mouth dissolving generics, combination products, Sterile/Lyophilized generics and Liquids/Dry syrups.

Aurobindo has filed 112 DMFs and 100 ANDAs for the USA market alone in addition to filings in other countries. The pace of filings is matched by rapid product approvals from various markets. Till date Aurobindo received 49 ANDA approvals (both final and tentative) from US alone. Aurobindo operates in over 100 countries and markets over 180 APIs and 250 formulations.